“HilleVax is advancing our HIL-214 clinical development program to potentially bring the first norovirus vaccine to market,” said Rob Hershberg, MD, PhD, Chairman and CEO of HilleVax. “We have continued to progress the NEST-IN1 clinical trial and remain on track to report topline data by mid-2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HLVX:
- HilleVax to Present at Upcoming Investor Conferences
- HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
- HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
- HilleVax Announces Pricing of Public Offering of Common Stock
- HilleVax 8M share Spot Secondary priced at $12.50
